Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes

BACKGROUND: Pegvisomant (PEGV) is widely used, alone or with somatostatin analogs (SSA), for GH-secreting pituitary tumors poorly controlled by SSAs alone. No information is available on specific indications for or relative efficacies of PEGV?+?SSA versus PEGV monotherapy. Aim of our study was to ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Bianchi, Antonio, Valentini, Ferdinando, Iuorio, Raffaella, Poggi, Maurizio, Baldelli, Roberto, Passeri, Marina, Giampietro, Antonella, Tartaglione, Linda, Chiloiro, Sabrina, Appetecchia, Marialuisa, Gargiulo, Patrizia, Fabbri, Andrea, Toscano, Vincenzo, Pontecorvi, Alfredo, De Marinis, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3695848/
https://www.ncbi.nlm.nih.gov/pubmed/23799893
http://dx.doi.org/10.1186/1756-9966-32-40

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3695848/
https://www.ncbi.nlm.nih.gov/pubmed/23799893
http://dx.doi.org/10.1186/1756-9966-32-40

Ejemplares similares